About MEAJO | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions to authors | Online submission | Subscribe | Advertise | Contact | Login 
Middle East African Journal of Ophthalmology Middle East African Journal of Ophthalmology
Users Online: 91   Home Print this page Email this page Small font sizeDefault font sizeIncrease font size
Year : 2017  |  Volume : 24  |  Issue : 3  |  Page : 136-142

Intravitreal bevacizumab for choroidal neovascularization associated with angioid streaks: Long-term results

1 Department of Ophthalmology, PSG Institute of Medical Sciences and Research, Coimbatore, Tamil Nadu; Consultant, Retina Services, The Eye Foundation, Coimbatore, Tamil Nadu, India
2 Consultant, Retina Services, The Eye Foundation, Coimbatore, Tamil Nadu, India
3 Consultant, Retina Services, The Eye Foundation, Coimbatore, Tamil Nadu; Consultant ophthalmologist, Divyadrishti Lasers Private Limited, Satara, Maharashtra, India
4 Department of Community Medicine, GCS Medical College, Ahmadabad, Gujarat, India
5 Department of Community Medicine, PSG Institute of Medical Sciences and Research, Coimbatore, Tamil Nadu, India

Correspondence Address:
T Lekha
F 5, Marutham Maagnus, V.K.K. Menon Road, New Siddhapudur, Coimbatore - 641 044, Tamil Nadu
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/meajo.MEAJO_17_17

Rights and Permissions

Purpose: The purpose of the study was to evaluate the long-term efficacy and safety of intravitreal bevacizumab (IVB) in the treatment of choroidal neovascularization (CNV) secondary to angioid streaks (AS). Materials and Methods: Noncomparative, interventional retrospective case series involving ten patients (15 eyes) with a minimum follow-up of 25 months following IVB for AS-associated CNV. Demographic and clinical details at baseline and during follow-up were collected from patient records. Detailed clinical examination was followed by fundus fluorescein angiography and optical coherence tomography to confirm CNV. Both primary and recurrent CNVs were treated with monthly injections of IVB till the lesion stabilized. Primary outcome measures were the percentage of patients with stable or improved visual acuity (VA) and with stable or decreased central retinal thickness (CRT) at the last visit. Secondary outcome measure was the incidence of ocular and systemic complications. Results: Recurrence was observed in 11 eyes (73.33%) over a mean follow-up of 57.33 months (range: 25–100). A mean number of injections administered was 5.60. VA improved or stabilized in 73.33% and deteriorated in 26.67% of eyes at the final visit. Mean CRT improved from 324.40 μm at baseline to 265.53 μm at final visit, which was statistically significant. Complications observed were ocular hypertension in one patient and thromboembolic event in another patient. Conclusions: IVB appears to be a safe and effective option to treat CNV and to preserve vision over a prolonged period. It cannot eliminate the risk of recurrent CNV indicating the need for more effective treatments to arrest this visually debilitating condition.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded165    
    Comments [Add]    

Recommend this journal